Brokerages Anticipate Charles River Laboratories Intl. Inc (NYSE:CRL) to Post $1.56 Earnings Per Share

Analysts expect Charles River Laboratories Intl. Inc (NYSE:CRL) to report earnings of $1.56 per share for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for Charles River Laboratories Intl.’s earnings, with the highest EPS estimate coming in at $1.61 and the lowest estimate coming in at $1.52. Charles River Laboratories Intl. posted earnings per share of $1.62 in the same quarter last year, which indicates a negative year over year growth rate of 3.7%. The company is scheduled to issue its next earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Charles River Laboratories Intl. will report full-year earnings of $6.48 per share for the current fiscal year, with EPS estimates ranging from $6.46 to $6.50. For the next fiscal year, analysts anticipate that the business will report earnings of $7.35 per share, with EPS estimates ranging from $7.14 to $7.55. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Tuesday, May 7th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.38 by $0.02. The firm had revenue of $604.57 million for the quarter, compared to analyst estimates of $587.65 million. Charles River Laboratories Intl. had a net margin of 9.63% and a return on equity of 23.03%. Charles River Laboratories Intl.’s revenue was up 22.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.29 EPS.

Several equities research analysts have recently commented on CRL shares. Zacks Investment Research cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Svb Leerink assumed coverage on Charles River Laboratories Intl. in a research note on Monday. They issued an “outperform” rating and a $155.00 price target on the stock. Evercore ISI restated an “outperform” rating and issued a $160.00 price objective on shares of Charles River Laboratories Intl. in a report on Tuesday, April 30th. Leerink Swann began coverage on Charles River Laboratories Intl. in a report on Monday. They set an “outperform” rating on the stock. Finally, Barclays raised their price objective on Charles River Laboratories Intl. from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, March 18th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Charles River Laboratories Intl. presently has a consensus rating of “Buy” and a consensus target price of $146.27.

In other news, Director George Massaro sold 1,002 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $131.38, for a total transaction of $131,642.76. Following the completion of the transaction, the director now directly owns 11,204 shares of the company’s stock, valued at approximately $1,471,981.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William D. Barbo sold 4,905 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total transaction of $613,909.80. Following the completion of the transaction, the insider now directly owns 25,859 shares of the company’s stock, valued at $3,236,512.44. The disclosure for this sale can be found here. Insiders have sold 9,047 shares of company stock worth $1,168,322 in the last quarter. Company insiders own 1.80% of the company’s stock.

A number of institutional investors have recently made changes to their positions in CRL. Fort L.P. purchased a new position in Charles River Laboratories Intl. during the 4th quarter valued at about $27,000. Tompkins Financial Corp boosted its position in shares of Charles River Laboratories Intl. by 63.1% in the first quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock worth $27,000 after purchasing an additional 77 shares during the period. Riverview Trust Co bought a new position in shares of Charles River Laboratories Intl. in the fourth quarter worth approximately $30,000. Sageworth Trust Co bought a new position in shares of Charles River Laboratories Intl. during the first quarter worth $37,000. Finally, Cresset Asset Management LLC purchased a new stake in Charles River Laboratories Intl. during the first quarter valued at $47,000. 94.72% of the stock is currently owned by institutional investors and hedge funds.

Shares of CRL opened at $131.28 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.63 and a quick ratio of 1.39. The company has a market capitalization of $6.48 billion, a P/E ratio of 21.77, a price-to-earnings-growth ratio of 1.71 and a beta of 1.05. Charles River Laboratories Intl. has a 52-week low of $103.00 and a 52-week high of $149.07.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: What are the FAANG Stocks?

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.